Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2778 - TRIUMPH Study: A multicenter phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer (EPOC1602)

Date

09 Sep 2017

Session

Poster display session

Presenters

Yoshiaki Nakamura

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

Y. Nakamura1, W. Okamoto2, K. Sawada3, Y. Komatsu4, K. Kato5, H. Taniguchi6, T. Kato7, T. Nishina8, T. Esaki9, H. Nomura10, M. Fukutani10, M. Fukui10, H. Hasegawa10, M. Yonemura10, N. Fuse10, A. Sato10, S. Fujii11, A. Ohtsu12, T. Yoshino1

Author affiliations

  • 1 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 Biobank Translational Research Support Section, Translational Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Department Of Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4 Department Of Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 5 Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 6 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 7 Department Of Surgery, Osaka National Hospital, 540-0006 - Osaka/JP
  • 8 Department Of Gastrointestinal Medical Oncology, Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 9 Department Of Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, Fukuoka/JP
  • 10 Clinical Research Support Office, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 11 Pathology Division, Research Center For Innovative Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 12 The Director Of A Hospital, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
More

Resources

Abstract 2778

Background

HER2 amplification is identified in approximately 5% out of RAS wild-type metastatic colorectal cancer (mCRC) and likely related to the resistance to EGFR blockade. Some preclinical and clinical studies have shown the efficacy of HER2-targeted therapy against HER2-positive mCRC. To identify this orphan-fractionated mCRC, we collaborate with the nationwide cancer genome screening project (SCRUM-Japan GI-SCREEN) by means of tissue/circulating tumor DNA (ctDNA) screening.

Trial design

TRIUMPH study is a multicenter phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive mCRC confirmed by either tissue or ctDNA analysis. Eligibility criteria includes histologically confirmed mCRC; ECOG PS ≤ 1; RAS wild-type and HER2-positive defined as IHC 3+ or FISH positive (HER2/CEP17 ratio ≥ 2.0) by means of tissue screening, or HER2-amplified and RAS wild-type identified from ctDNA (Guardant360); and refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, and anti-EGFR antibody. Enrolled patients will receive intravenous trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg) and pertuzumab (840 mg loading dose, followed by 420 mg) every 3 weeks. In addition, the natural history data of patients with HER2-positive and RAS wild-type who do not meet the eligibility will be followed as a historical control. The primary endpoint is objective response rate (ORR) by investigator’s assessment in patients with HER2 positive tumor confirmed by tissue analysis as well as ctDNA analysis, respectively. A sample size for each group is calculated to be 18 on the basis of a power of 80% to test the null hypothesis of ORR of less than 5% versus the alternative hypothesis of ORR of over 30%, at a one-sided alpha level of 0.025. Furthermore, ctDNA will be serially analyzed to investigate the resistance mechanisms; a key focus of current research is to provide clinically meaningful thresholds which may be used for identifying and implementing treatment changes.

Clinical trial identification

Legal entity responsible for the study

Wataru Okamoto

Funding

The Japan Agency for Medical Research and Development

Disclosure

W. Okamoto: Research funding from MSD. Y. Komatsu: Speakers\' Bureau: Taiho Pharmaceutical, Lilly, Chugai Pharma, Merck Serono, Novartis, Pfizer, Bayer. Honoraria: Novartis, Pfizer, Bayer. Research funding: Taiho Pharmaceutical, Lilly, MSD, Ono Pharmaceutical, Novartis, Bayer, Chugai Pharma, Yakult. K. Kato: Research funding: ONO, MSD, Shionogi. H. Taniguchi: Honoraria: Chugai Pharma. T. Kato: Speakers\' bureau: Chugai Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Bayer Yakuhin, Ltd., Sanofi S.A., Yakult Honsha Company, Limited. T. Nishina: Honoraria: Chugai Pharmaceutical Co. Ltd. T. Esaki: Honoraria: Chugai, Eli Lilly, Taiho, Merck Serono, Ono, Nihon Kayaku, Eisai. Research funding: Eli Lilly, Taiho, Novartis, Daiichi-Sankyo, DS pharma, AstraZeneca, Merck Serono, Ono, Boehringer, MSD. H. Nomura: Employment: Asahi-Kasei Pharma. A. Ohtsu: Research funding: Bristol-Myers Squibb. T. Yoshino: Research funding: GlaxoSmithKline K.K. and Boehringer-Ingelheim GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.